You are here:

paliperidone (palmitate 3-monthly) (Trevicta)

Advice

following an abbreviated submission:

paliperidone palmitate (Trevicta®) is accepted for use within NHS Scotland.

Indication under review: paliperidone palmitate (Trevicta®), a three-monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on one-monthly paliperidone palmitate injectable product.

This new formulation of paliperidone palmitate is administered every three months and is available at pro-rata cost to the monthly formulation.

Drug Details

Drug Name: paliperidone (palmitate 3-monthly) (Trevicta)
SMC Drug ID: 1181/16
Manufacturer: Janssen-Cilag Ltd
Indication: Paliperidone palmitate (Trevicta®), a three-monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on one-monthly paliperidone palmitate injectable product.
BNF Category:
Sub Category: 4.2 Drugs used in psychoses and related disorders
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 12 September 2016

Back